Brenzavvy vs Jardiance: Comparing Diabetes Medications

Introduction to Brenzavvy and Jardiance

When your care team mentions an SGLT2 inhibitor, you're hearing about a class of medications that work differently from older diabetes drugs like metformin or sulfonylureas. Instead of pushing the pancreas to make more insulin or helping cells use insulin better, SGLT2 inhibitors target the kidneys—instructing them to filter out excess glucose and send it into the urine rather than reabsorbing it back into the bloodstream.

Brenzavvy (bexagliflozin) and Jardiance (empagliflozin) both belong to this class. Brenzavvy is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Jardiance shares that same core indication but extends further: it's also approved to reduce cardiovascular risk in adults with established heart disease and to treat heart failure and chronic kidney disease.

Understanding the scope of each medication's approval matters when you're comparing options. If you're navigating type 2 diabetes alongside heart or kidney concerns, your A1C numbers are only part of the picture—your care team will weigh cardiovascular and renal protection as well. If your diagnosis is type 2 diabetes without those comorbidities, the comparison narrows to efficacy, tolerability, and cost.

Both medications are taken once daily as oral tablets. Neither replaces insulin for people who require it, and neither is indicated for type 1 diabetes or diabetic ketoacidosis. The editorial goal here is to decode what the research and prescribing information tell us about how these two drugs compare—efficacy, safety profile, and cost—so you can bring informed questions to your next appointment.

Efficacy Comparison

Both Brenzavvy (bexagliflozin) and Jardiance (empagliflozin) belong to the SGLT2 inhibitor class, and their core mechanism — blocking glucose reabsorption in the kidneys — produces similar glucose-lowering effects. Clinical data show that both medications lower A1C by 0.6 to 1.0 percent when used as part of a type 2 diabetes treatment plan. This range is consistent across the SGLT2 inhibitor class and represents a meaningful reduction for many people, though individual response varies.

A1C Reduction and Brenzavvy vs Jardiance

When comparing A1C outcomes, Brenzavvy and Jardiance perform nearly identically in head-to-head class data. Both medications produce A1C reductions in the 0.6 to 1.0 percent range, and neither has demonstrated a clear superiority in glucose control alone. If your primary goal is lowering A1C, either medication is likely to deliver comparable results — the choice between them often comes down to other factors like cardiovascular data, cost, or side-effect tolerance. Your care team can help you interpret what an A1C reduction means in the context of your overall diabetes management plan.

Weight Loss Effects

SGLT2 inhibitors also produce modest weight loss as a secondary benefit. Both Brenzavvy and Jardiance typically lead to 2 to 4 kg of weight loss over the course of treatment, with clinical data showing a mean placebo-adjusted weight loss of about 1.8 kg (typically ranging from 1 to 3 kg) over 24 weeks. This weight loss is driven by the calorie loss from glucose excreted in urine, not by appetite suppression or metabolic changes. The effect is consistent across the class, so neither medication offers a meaningful advantage in this area.

Cardiovascular Outcomes: A Key Difference

The most significant efficacy difference between Brenzavvy and Jardiance appears in cardiovascular outcomes data. Jardiance has demonstrated reductions in major adverse cardiovascular events (MACE) in large clinical trials, a benefit shared by other established SGLT2 inhibitors like Farxiga and Invokana. Brenzavvy, as a newer medication, does not yet have comparable cardiovascular outcomes data published or included in its FDA approval. For people with type 2 diabetes and existing cardiovascular disease — or those at high cardiovascular risk — this distinction matters. The ADA Standards of Care prioritize medications with proven cardiovascular benefit in these populations, which currently favors Jardiance over Brenzavvy.

If cardiovascular protection is part of your treatment goals, discuss this gap with your care team. Brenzavvy may still be appropriate for glucose control and weight management, but Jardiance (or another SGLT2 inhibitor with cardiovascular data) may be the preferred choice when heart protection is a priority.

Side Effects and Safety

Both Brenzavvy and Jardiance belong to the SGLT2 inhibitor class, which means they share a similar mechanism and, consequently, overlapping safety profiles. Understanding the common side effects and how they differ between the two medications helps frame conversations with your care team about which option might fit better with your individual health picture.

Common Adverse Reactions

The most frequently reported side effects for both medications center on the urinary and genital systems, a direct result of how SGLT2 inhibitors work. Jardiance is associated with urinary tract infections and increased urination, while Brenzavvy's common adverse reactions include increased urination, increased thirst, and urinary tract infections. Both medications also carry a risk of genital yeast infections, which occur more frequently in people taking SGLT2 inhibitors than in those on other diabetes medication classes.

Brenzavvy has a higher rate of injection site reactions compared to Jardiance, which makes sense given their different formulations: Brenzavvy is administered as a weekly subcutaneous injection, while Jardiance is an oral tablet taken once daily. Injection site reactions typically include redness, itching, or mild discomfort at the injection location and often diminish as the body adjusts to the medication.

Safety Considerations Across the Class

Beyond the most common side effects, both medications carry class-wide warnings that apply to all SGLT2 inhibitors. These include risks of dehydration (especially in older adults or those taking diuretics), low blood pressure, and diabetic ketoacidosis in rare cases. If you're managing other conditions alongside type 2 diabetes—particularly kidney disease or heart conditions—your care team will evaluate whether an SGLT2 inhibitor is appropriate and monitor you accordingly.

For a broader context on how blood sugar targets and medication adjustments work together, see What's a Normal Blood Sugar Level? Ranges and Targets.

The safety profile you experience will depend on your individual health history, other medications you're taking, and how your body responds to the drug. Neither medication is universally "safer"—the question is which side-effect profile is more manageable for you, and that's a decision best made with your prescriber's input.

Cost Analysis

Understanding the cost difference between Brenzavvy and Jardiance matters when you're planning long-term diabetes management. Both medications belong to the SGLT2 inhibitor class, but their pricing structures and insurance coverage patterns differ in ways that can significantly affect your out-of-pocket expenses.

Insurance Coverage Patterns

Brenzavvy and Jardiance occupy different positions on many insurance formularies. Three major payers — including UnitedHealthcare — require step therapy for Brenzavvy but not for Jardiance. Step therapy means you must try and fail on another medication before your insurer will cover Brenzavvy, which can delay access and add administrative burden to your care.

This coverage gap doesn't necessarily mean Jardiance is always more accessible. Formulary placement changes frequently, and your specific plan's tier structure determines your copay. Always verify your own plan's coverage before assuming one medication will cost less than the other.

Health System Cost Data

One health system documented substantial savings after switching from Jardiance to Brenzavvy as the preferred SGLT2 inhibitor. The plan anticipated $1.6 million in annual savings but realized more than $3.4 million in actual savings with their commercial population. That gap between projected and realized savings suggests Brenzavvy's lower acquisition cost translated to larger-than-expected reductions in total drug spend.

Across the SGLT2 inhibitor class, per-member-per-month (PMPM) spending declined from $2.48 in 2024 to $2.23 in 2025 — a 10.2% reduction. This trend reflects broader shifts in formulary management and manufacturer pricing strategies, not just the Brenzavvy vs Jardiance comparison.

What This Means for Your Budget

These institutional savings don't automatically translate to lower costs at the pharmacy counter. Your out-of-pocket expense depends on your insurance plan's negotiated rate, your deductible status, and whether you've hit your annual out-of-pocket maximum. A medication that saves your insurer money may still carry a high copay if it sits on a non-preferred tier.

Manufacturer copay cards and patient assistance programs exist for both medications, but eligibility rules vary. If you have commercial insurance and face a high copay, ask your prescriber's office whether a copay card is available and whether it applies to your specific plan. Medicare and Medicaid patients are generally excluded from manufacturer copay assistance due to federal anti-kickback rules.

For a broader look at how blood sugar targets and medication decisions intersect with cost planning, see What's a Normal Blood Sugar Level? Ranges and Targets.

Conclusion

Choosing between Brenzavvy and Jardiance comes down to balancing clinical evidence, cost, and your individual health priorities. Both medications belong to the SGLT2 inhibitor class and work through the same mechanism — blocking glucose reabsorption in the kidneys to lower blood sugar. For many people with type 2 diabetes, either drug can effectively reduce A1C when combined with diet and exercise.

Jardiance carries a significant advantage in cardiovascular and kidney protection. Clinical trials have demonstrated that Jardiance reduces the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — in people with established heart disease. It also slows kidney disease progression in people with diabetic kidney disease. Brenzavvy, as a newer agent, does not yet have published cardiovascular outcomes data of this scope. If you have a history of heart disease, heart failure, or chronic kidney disease, that evidence gap matters, and Jardiance may be the safer choice pending further research on Brenzavvy.

Cost and Access

Brenzavvy's primary advantage is cost. Health systems that have switched from Jardiance to Brenzavvy as a preferred agent have reported annual savings exceeding $3.4 million in commercial populations — more than double initial projections. For patients paying out-of-pocket or facing high copays, Brenzavvy's lower list price can make long-term adherence more feasible. However, your actual cost depends on your insurance formulary, manufacturer assistance programs, and pharmacy. Always confirm your specific copay before filling a new prescription.

Side-effect profiles are similar for both drugs: genital yeast infections, urinary tract infections, and increased urination are common. Both carry a small risk of diabetic ketoacidosis and dehydration, particularly in people taking insulin or during illness. Neither drug has a clear safety edge over the other in head-to-head comparisons.

Who Should Choose What

Jardiance is the evidence-backed choice if you have:

• Established cardiovascular disease (prior heart attack, stroke, or coronary artery disease)
• Heart failure with reduced or preserved ejection fraction
• Chronic kidney disease with albuminuria

Brenzavvy may be appropriate if:

• You have type 2 diabetes without cardiovascular or kidney complications
• Cost is a significant barrier to adherence
• Your insurance formulary strongly favors Brenzavvy

This is not a decision to make in isolation. Bring this comparison to your next appointment. Ask your care team whether the cardiovascular and kidney data for Jardiance apply to your situation, or whether Brenzavvy's cost savings outweigh the evidence gap. Your provider can review your full medical history, current medications, and insurance coverage to recommend the option that fits your clinical profile and budget. For more context on how blood sugar targets and A1C goals factor into medication decisions, see our guide on A1C conversion and what your number means.

Neither medication is inherently better — the right choice depends on what you're treating and what you can afford to take consistently. The best diabetes medication is the one you can access, tolerate, and take as prescribed.